Built for automation of enterprise-level migrations across legacy Exchange Servers and Microsoft 365 without running complex PowerShell scripts. HOUSTON, Feb. 17Built for automation of enterprise-level migrations across legacy Exchange Servers and Microsoft 365 without running complex PowerShell scripts. HOUSTON, Feb. 17

Stellar® Launches New Software for Seamless, Script-Free Exchange Mailbox Migrations

2026/02/17 22:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Built for automation of enterprise-level migrations across legacy Exchange Servers and Microsoft 365 without running complex PowerShell scripts.

HOUSTON, Feb. 17, 2026 /PRNewswire/ — While businesses increasingly shift dependency on hybrid and cloud-based email systems, Stellar introduces its New Migrator for Exchange. This software is a robust tool designed with the objective to make mailbox migrations simpler across hosted Exchange Servers and Microsoft 365. The Stellar Migrator for Exchange ensures fast, easy, accurate, and cost-effective migrations that allow organizations to remain operational with zero downtime.

Stellar Migrator for Exchange is a user-friendly software, eliminating the need for intricate PowerShell scripts or professional expertise. It exclusively supports mailbox migrations between Exchange Server and Microsoft 365, including tenant-to-tenant transfers across the same or different domains and forests. This allows mailbox migrations across diverse environments through a single, unified solution.

The software is designed to deliver measurable outcomes for MSPs and internal IT teams. It adds value to operations by reducing migration time, eliminating manual errors, and ensuring uninterrupted business operations. Built to handle high-volume and multi-tenant environments, the solution automates mailbox mapping, supports incremental synchronization, and enables zero-downtime migrations, which allow teams to complete projects faster while maintaining full control and visibility.

The cutover, staged, and hybrid migration methods allow organizations to choose their migration strategy based on business needs, while incremental (delta) migration ensures that only new or modified data is transferred. Real-time monitoring and detailed reporting give administrators visibility into progress. This allows system admins to identify failed migrations with the software’s re-run capabilities.

“Mailbox migration is no longer an isolated IT event. With the hybrid and multi-tenant environments, it is a continuous business requirement. MSP and enterprise IT teams need migration support and not add to their operational burden. We designed Stellar® Migrator for Exchange Software to eliminate complexity at scale,” said Sunil Chandna, Founder & CEO of Stellar.

Stellar Migrator for Exchange is available now with a free trial supporting migration of 2 mailboxes. Priced from as low as $3 per mailbox for 500-mailbox migration. For a customized quote for enterprise level and more information, visit https://www.stellarinfo.com/exchange-migration.php

About Stellar: With foundation laid in 1993, Stellar® today is a market leader in Data Care Services. With expertise in Data Recovery, Data Erasure, Mailbox Conversion, & File Repair Software, Online Solutions and In-Lab Services, we serve 3 Million+ customers in over 190 countries. We build trustworthy technology marked by the ISO 9001, ISO 27001, NIST certifications, and HIPAA verification.

Follow us on: Instagram, Youtube, LinkedIn, X, Facebook

Media Contact:
Afroz Alam
Phone: +1 877 778 6087
Email: 409173@email4pr.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stellar-launches-new-software-for-seamless-script-free-exchange-mailbox-migrations-302688697.html

SOURCE Stellar

Market Opportunity
Cloud Logo
Cloud Price(CLOUD)
$0.01816
$0.01816$0.01816
-0.05%
USD
Cloud (CLOUD) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage